Tepha

About Tepha

Tepha, Inc., established in 1998 and headquartered in Lexington, MA, operates as a developer and manufacturer of medical devices focused on the biomaterials market. The company was founded by Dr. A. Anthony Sinskey and originated as a spin-off from Metabolix, Inc., holding exclusive licenses for technology initially developed at the Massachusetts Institute of Technology (MIT). In July 2021, the firm was acquired by Becton, Dickinson and Company (BD), a global medical technology company, marking a strategic move for BD to vertically integrate a key supply chain component and expand its capabilities in the surgical mesh market.

Tepha's core business revolves around its proprietary resorbable polymer, Poly-4-hydroxybutyrate (P4HB), which is produced via a patented recombinant DNA technology and fermentation process. This technology allows for the creation of a portfolio of bioabsorbable medical devices with tailored mechanical properties and degradation rates to support the body's natural healing process. The business model is centered on developing, manufacturing, and supplying these P4HB-based products, both directly and through partnerships with other medical device companies. Its clients are primarily in the medical field, including surgeons and hospitals that perform soft tissue repair, reconstruction, and regeneration procedures.

The company's product portfolio is extensive, featuring devices for various surgical applications. A cornerstone product is the TephaFLEX Absorbable Suture, which received its first FDA clearance in 2007. Other commercial products include surgical meshes, films, and scaffolds designed for hernia repair, plastic and reconstructive surgery, and orthopedic soft tissue repair. The GalaFLEX portfolio, for instance, consists of bioresorbable scaffolds used for soft tissue support in procedures requiring reinforcement. The defining feature of Tepha's P4HB products is their combination of strength, flexibility, and biocompatibility, offering prolonged strength retention while being safely absorbed by the body. This positions them as a compelling alternative to other commercially available resorbable polymers, as they have been shown to be less inflammatory.